Jelle Rindert Miedema
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jelle Rindert Miedema has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Marlies S. Wijsenbeek
Department of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
3 shared publications- Ana Cordeiro
Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal
2 shared publications Argyrios Tzouvelekis
Department of Respiratory Medicine, University of Patras, Patras, Greece
2 shared publicationsCaroline E. Broos
Department of Pulmonary Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
2 shared publications- Catharina C. Moor
Department of Respiratory Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
2 shared publications Henrik Endeman
Department of Intensive Care, Erasmus Medical Center, Rotterdam, Netherlands
2 shared publications
Latest Publications
- Open Access
- 5 October 2024
- Published by Elsevier in Autoimmunity Reviews
- Vol. 23 (10) , 103641
Corrigendum to “Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease” [Autoimmunity Reviews - Volume 23, Issue 6, June 2024, 103582]
- 5 October 2024
- Published by Elsevier in Autoimmunity Reviews
- Vol. 23 (10) , 103641
Open AccessCorrigendum to “Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease” [Autoimmunity Reviews - Volume 23, Issue 6, June 2024, 103582]
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2482
Reduced CTLA-4 expression in Th17 cells or Tregs induces T cell activation: implications for sarcoidosis
Objective: Sarcoidosis is a granulomatous disease in which CD4+ T cells are central to disease pathogenesis. We previously found decreased expression of the co-inhibitory marker cytotoxic T-lymphocyte antigen 4 (CTLA-4) in Th17 cells and regulatory T cells (Tregs) in lymph nodes (LN) of patients. However, the effects of low CTLA-4 expression in Th17 cells or Tregs are unknown. Methods: Using the Cre-LoxP system, we generated mice in which the Ctla4 gene was specifically targeted in IL-17-producing T cells on one (17-Ctla4+/-) or both alleles (17-Ctla4−/-), as well as mice haplo-insufficient for CTLA4 in Tregs (Treg-Ctla4+/-). The immune status of the mice was evaluated at 8-30 weeks, using immunohistochemistry and multi-color flow cytometry. Results: We did not find evidence for immune dysregulation in 17-Ctla4+/- mice. In contrast, spleen and LN of 17-Ctla4−/- mice showed a significant increase in the proportions of CCR6+ T cells, increased fractions of cells expressing the ICOS activation marker within total CD4+ memory T (Tm) cells, CCR6+ T cells and Tregs, and signs of substantial B cell activation, but no granuloma formation. Upon collagen immunization, splenic CD4+ T cells exhibited increased cytokine production, but no enhanced arthritis symptoms or granuloma formation. In Treg-Ctla4+/- mice, Tregs were expanded and, interestingly, the fractions of ICOS+ cells were increased in the Tm, CCR6+ T cell and Treg populations. Conclusions: Our results indicate that expression levels of CTLA-4 in Tregs are critical for the maintenance of immune homeostasis. In IL-17-producing T cells CTLA-4 expression appears less critical and only a complete deficiency induces immune dysregulation.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA2482
Reduced CTLA-4 expression in Th17 cells or Tregs induces T cell activation: implications for sarcoidosis
Objective: Sarcoidosis is a granulomatous disease in which CD4+ T cells are central to disease pathogenesis. We previously found decreased expression of the co-inhibitory marker cytotoxic T-lymphocyte antigen 4 (CTLA-4) in Th17 cells and regulatory T cells (Tregs) in lymph nodes (LN) of patients. However, the effects of low CTLA-4 expression in Th17 cells or Tregs are unknown. Methods: Using the Cre-LoxP system, we generated mice in which the Ctla4 gene was specifically targeted in IL-17-producing T cells on one (17-Ctla4+/-) or both alleles (17-Ctla4−/-), as well as mice haplo-insufficient for CTLA4 in Tregs (Treg-Ctla4+/-). The immune status of the mice was evaluated at 8-30 weeks, using immunohistochemistry and multi-color flow cytometry. Results: We did not find evidence for immune dysregulation in 17-Ctla4+/- mice. In contrast, spleen and LN of 17-Ctla4−/- mice showed a significant increase in the proportions of CCR6+ T cells, increased fractions of cells expressing the ICOS activation marker within total CD4+ memory T (Tm) cells, CCR6+ T cells and Tregs, and signs of substantial B cell activation, but no granuloma formation. Upon collagen immunization, splenic CD4+ T cells exhibited increased cytokine production, but no enhanced arthritis symptoms or granuloma formation. In Treg-Ctla4+/- mice, Tregs were expanded and, interestingly, the fractions of ICOS+ cells were increased in the Tm, CCR6+ T cell and Treg populations. Conclusions: Our results indicate that expression levels of CTLA-4 in Tregs are critical for the maintenance of immune homeostasis. In IL-17-producing T cells CTLA-4 expression appears less critical and only a complete deficiency induces immune dysregulation.
- Open Access
- 27 July 2024
- Published by Elsevier in Autoimmunity Reviews
- Vol. 23 (6) , 103582
Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease
- 27 July 2024
- Published by Elsevier in Autoimmunity Reviews
- Vol. 23 (6) , 103582
Open AccessPractical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease
- Top Cited PapersOpen Access
- 10 May 2024
- Published by Elsevier in Journal of Autoimmunity
- Vol. 149, 103247
The immunopathogenesis of sarcoidosis
- 10 May 2024
- Published by Elsevier in Journal of Autoimmunity
- Vol. 149, 103247
Top Cited PapersOpen AccessThe immunopathogenesis of sarcoidosis
- Open Access
- 7 May 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-12
Increased proportions of circulating PD-1+ CD4+ memory T cells and PD-1+ regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis
Background: The treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4+ T cells are central in sarcoid pathogenesis and their phenotype in peripheral blood (PB) associates with disease course. We hypothesized that the phenotype of circulating T cells in patients with sarcoidosis may correlate with the response to prednisone treatment. Therefore, we aimed to correlate frequencies and phenotypes of circulating T cells at baseline with the pulmonary function response at 3 and 12 months during prednisone treatment in patients with pulmonary sarcoidosis. Methods: We used multi-color flow cytometry to quantify activation marker expression on PB T cell populations in 22 treatment-naïve patients and 21 healthy controls (HCs). Pulmonary function tests at baseline, 3 and 12 months were used to measure treatment effect. Results: Patients with sarcoidosis showed an absolute forced vital capacity (FVC) increase of 14.2% predicted (± 10.6, p < 0.0001) between baseline and 3 months. Good response to prednisone (defined as absolute FVC increase of ≥ 10% predicted) was observed in 12 patients. CD4+ memory T cells and regulatory T cells from patients with sarcoidosis displayed an aberrant phenotype at baseline, compared to HCs. Good responders at 3 months had significantly increased baseline proportions of PD-1+CD4+ memory T cells and PD-1+ regulatory T cells, compared to poor responders and HCs. Moreover, decreased fractions of CD25+ cells and increased fractions of PD-1+ cells within the CD4+ memory T cell population correlated with ≥ 10% FVC increase at 12 months. During treatment, the aberrantly activated phenotype of memory and regulatory T cells reversed. Conclusions: Increased proportions of circulating PD-1+CD4+ memory T cells and PD-1+ regulatory T cells and decreased proportions of CD25+CD4+ memory T cells associate with good FVC response to prednisone in pulmonary sarcoidosis, representing promising new blood biomarkers for prednisone efficacy. Trial registration: NL44805.078.13
- 7 May 2024
- Published by Springer Nature in Respiratory Research
- Vol. 25 (1) , 1-12
Open AccessIncreased proportions of circulating PD-1+ CD4+ memory T cells and PD-1+ regulatory T cells associate with good response to prednisone in pulmonary sarcoidosis
Background: The treatment response to corticosteroids in patients with sarcoidosis is highly variable. CD4+ T cells are central in sarcoid pathogenesis and their phenotype in peripheral blood (PB) associates with disease course. We hypothesized that the phenotype of circulating T cells in patients with sarcoidosis may correlate with the response to prednisone treatment. Therefore, we aimed to correlate frequencies and phenotypes of circulating T cells at baseline with the pulmonary function response at 3 and 12 months during prednisone treatment in patients with pulmonary sarcoidosis. Methods: We used multi-color flow cytometry to quantify activation marker expression on PB T cell populations in 22 treatment-naïve patients and 21 healthy controls (HCs). Pulmonary function tests at baseline, 3 and 12 months were used to measure treatment effect. Results: Patients with sarcoidosis showed an absolute forced vital capacity (FVC) increase of 14.2% predicted (± 10.6, p < 0.0001) between baseline and 3 months. Good response to prednisone (defined as absolute FVC increase of ≥ 10% predicted) was observed in 12 patients. CD4+ memory T cells and regulatory T cells from patients with sarcoidosis displayed an aberrant phenotype at baseline, compared to HCs. Good responders at 3 months had significantly increased baseline proportions of PD-1+CD4+ memory T cells and PD-1+ regulatory T cells, compared to poor responders and HCs. Moreover, decreased fractions of CD25+ cells and increased fractions of PD-1+ cells within the CD4+ memory T cell population correlated with ≥ 10% FVC increase at 12 months. During treatment, the aberrantly activated phenotype of memory and regulatory T cells reversed. Conclusions: Increased proportions of circulating PD-1+CD4+ memory T cells and PD-1+ regulatory T cells and decreased proportions of CD25+CD4+ memory T cells associate with good FVC response to prednisone in pulmonary sarcoidosis, representing promising new blood biomarkers for prednisone efficacy. Trial registration: NL44805.078.13
- Open Access
- 18 October 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 149, 103120
Circulating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome
- 18 October 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 149, 103120
Open AccessCirculating T cells in sarcoidosis have an aberrantly activated phenotype that correlates with disease outcome
- Open Access
- 8 August 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1204433
Antibodies against angiotensin II receptor type 1 and endothelin A receptor are increased in COVID-19 patients
Background: Increased titers of autoantibodies targeting the G-protein-coupled receptors angiotensin II type 1 receptor (AT1R) and endotelin-1 type A receptor (ETAR) are associated with severe coronavirus disease 2019 (COVID-19) infection. The aim of this study was to determine whether 1) these antibodies are specifically related to COVID-19 disease pathogenesis or increased during any severe respiratory illness, 2) if they are formed during illness, and 3) if they correlate with inflammatory markers or long-term symptoms.Methods: Antibodies against AT1R, ETAR, and antinuclear antibodies (ANAs) were measured in n=40 prospectively enrolled COVID-19 patients and n=207 COVID-19 patients included in a biobank. Clinical and laboratory findings were prospectively and retrospectively assessed in both cohorts, and results were combined for analysis. The presence of auto-antibodies against AT1R or ETAR in peripheral blood was compared between hospitalized patients with COVID-19 and controls (n=39). Additionally, AT1R and ETAR titers were compared between patients with an unfavorable disease course, defined as intensive care admission and/or death during hospital admission (n=121), to those with a favorable disease course (n=126). A subset of intubated patients with severe COVID-19 were compared to intubated patients with acute respiratory distress syndrome (ARDS) due to any other cause.Results: Significantly increased AT1R and ETAR antibody titers were found in COVID-19 patients compared to controls, while titers were equal between favorable and unfavorable COVID-19 disease course groups. On ICU, intubated patients with COVID-19 had significantly increased AT1R and ETAR titers compared to patients with ARDS due to any other cause. The titers did not correlate with baseline inflammatory markers during admission or with diffusion capacity, cognitive impairment, or fatigue measured at 3 months follow-up.Conclusions: In patients hospitalized for COVID-19, antibodies against AT1R and ETAR are increased compared to controls and patients with ARDS due to other causes than COVID-19. The baseline antibody titers do not correlate with inflammatory markers or long-term symptoms in this study.
- 8 August 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1204433
Open AccessAntibodies against angiotensin II receptor type 1 and endothelin A receptor are increased in COVID-19 patients
Background: Increased titers of autoantibodies targeting the G-protein-coupled receptors angiotensin II type 1 receptor (AT1R) and endotelin-1 type A receptor (ETAR) are associated with severe coronavirus disease 2019 (COVID-19) infection. The aim of this study was to determine whether 1) these antibodies are specifically related to COVID-19 disease pathogenesis or increased during any severe respiratory illness, 2) if they are formed during illness, and 3) if they correlate with inflammatory markers or long-term symptoms.Methods: Antibodies against AT1R, ETAR, and antinuclear antibodies (ANAs) were measured in n=40 prospectively enrolled COVID-19 patients and n=207 COVID-19 patients included in a biobank. Clinical and laboratory findings were prospectively and retrospectively assessed in both cohorts, and results were combined for analysis. The presence of auto-antibodies against AT1R or ETAR in peripheral blood was compared between hospitalized patients with COVID-19 and controls (n=39). Additionally, AT1R and ETAR titers were compared between patients with an unfavorable disease course, defined as intensive care admission and/or death during hospital admission (n=121), to those with a favorable disease course (n=126). A subset of intubated patients with severe COVID-19 were compared to intubated patients with acute respiratory distress syndrome (ARDS) due to any other cause.Results: Significantly increased AT1R and ETAR antibody titers were found in COVID-19 patients compared to controls, while titers were equal between favorable and unfavorable COVID-19 disease course groups. On ICU, intubated patients with COVID-19 had significantly increased AT1R and ETAR titers compared to patients with ARDS due to any other cause. The titers did not correlate with baseline inflammatory markers during admission or with diffusion capacity, cognitive impairment, or fatigue measured at 3 months follow-up.Conclusions: In patients hospitalized for COVID-19, antibodies against AT1R and ETAR are increased compared to controls and patients with ARDS due to other causes than COVID-19. The baseline antibody titers do not correlate with inflammatory markers or long-term symptoms in this study.
- Open Access
- 28 May 2022
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-6
Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
Background: Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aimed to investigate the safety, tolerability and efficacy of pirfenidone in asbestosis patients with a progressive phenotype. Methods: This was a multicenter prospective study in asbestosis patients with progressive lung function decline. After a 12-week observational period, patients were treated with pirfenidone 801 mg three times a day. Symptoms and adverse events were evaluated weekly and patients completed online patient-reported outcomes measures. At baseline, start of therapy, 12 and 24 weeks, in hospital measurement of lung function and a 6 min walking test were performed. Additionally, patients performed daily home spirometry measurements. Results: In total, 10 patients were included of whom 6 patients (66.7%) experienced any adverse events during the study period. Most frequently reported adverse events were fatigue, rash, anorexia and cough, which mostly occurred intermittently and were reported as not very bothersome. No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found. Home spirometry demonstrated a FVC decline in 12 weeks before start of pirfenidone, while FVC did not decline during the 24 week treatment phase, but this difference was not statistically significant. Conclusions: Treatment with pirfenidone in asbestosis has an acceptable safety and tolerability profile and home spirometry data suggest this antifibrotic treatment might attenuate FVC decline in progressive asbestosis. Trial registration MEC-2018-1392; EudraCT number: 2018-001781-41
- 28 May 2022
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-6
Open AccessSafety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
Background: Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aimed to investigate the safety, tolerability and efficacy of pirfenidone in asbestosis patients with a progressive phenotype. Methods: This was a multicenter prospective study in asbestosis patients with progressive lung function decline. After a 12-week observational period, patients were treated with pirfenidone 801 mg three times a day. Symptoms and adverse events were evaluated weekly and patients completed online patient-reported outcomes measures. At baseline, start of therapy, 12 and 24 weeks, in hospital measurement of lung function and a 6 min walking test were performed. Additionally, patients performed daily home spirometry measurements. Results: In total, 10 patients were included of whom 6 patients (66.7%) experienced any adverse events during the study period. Most frequently reported adverse events were fatigue, rash, anorexia and cough, which mostly occurred intermittently and were reported as not very bothersome. No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found. Home spirometry demonstrated a FVC decline in 12 weeks before start of pirfenidone, while FVC did not decline during the 24 week treatment phase, but this difference was not statistically significant. Conclusions: Treatment with pirfenidone in asbestosis has an acceptable safety and tolerability profile and home spirometry data suggest this antifibrotic treatment might attenuate FVC decline in progressive asbestosis. Trial registration MEC-2018-1392; EudraCT number: 2018-001781-41
- Open Access
- 28 June 2021
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 27 (5) , 439-447
Drug-induced sarcoidosis-like reactions
Purpose of review: Sarcoidosis is a complex granulomatous disease of unknown cause. Several drug categories are able to induce a systemic granulomatous indistinguishable from sarcoidosis, known as drug-induced sarcoidosis-like reaction (DISR). This granulomatous inflammation can resolve if the medication is discontinued. In this review, we discuss recent literature on medication associated with DISR, possible pathophysiology, clinical features, and treatment. Recent findings: Recently, increasing reports on DISR have expanded the list of drugs associated with the systemic granulomatous eruption. Most reported drugs can be categorized as combination antiretroviral therapy, tumor necrosis factor-α antagonist, interferons, and immune checkpoint inhibitors, but reports on other drugs are also published. The proposed mechanism is enhancement of the aberrant immune response which results in systemic granuloma formation. It is currently not possible to know whether DISR represents a separate entity or is a triggered but ‘true’ sarcoidosis. As DISRs may cause minimal symptoms, treatment is not always necessary and the benefits of continuing the offending drug should be weighed against clinical symptoms and organ dysfunction. Treatment may involve immunosuppressive medication that is used for sarcoidosis treatment. Summary: In this article, we review recent insights in DISR: associated drug categories, clinical presentation, diagnosis, and treatment. Additionally, we discuss possible mechanisms of DISR which can add to our knowledge of sarcoidosis pathophysiology.
- 28 June 2021
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 27 (5) , 439-447
Open AccessDrug-induced sarcoidosis-like reactions
Purpose of review: Sarcoidosis is a complex granulomatous disease of unknown cause. Several drug categories are able to induce a systemic granulomatous indistinguishable from sarcoidosis, known as drug-induced sarcoidosis-like reaction (DISR). This granulomatous inflammation can resolve if the medication is discontinued. In this review, we discuss recent literature on medication associated with DISR, possible pathophysiology, clinical features, and treatment. Recent findings: Recently, increasing reports on DISR have expanded the list of drugs associated with the systemic granulomatous eruption. Most reported drugs can be categorized as combination antiretroviral therapy, tumor necrosis factor-α antagonist, interferons, and immune checkpoint inhibitors, but reports on other drugs are also published. The proposed mechanism is enhancement of the aberrant immune response which results in systemic granuloma formation. It is currently not possible to know whether DISR represents a separate entity or is a triggered but ‘true’ sarcoidosis. As DISRs may cause minimal symptoms, treatment is not always necessary and the benefits of continuing the offending drug should be weighed against clinical symptoms and organ dysfunction. Treatment may involve immunosuppressive medication that is used for sarcoidosis treatment. Summary: In this article, we review recent insights in DISR: associated drug categories, clinical presentation, diagnosis, and treatment. Additionally, we discuss possible mechanisms of DISR which can add to our knowledge of sarcoidosis pathophysiology.
- Open Access
- 13 May 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 684142
Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course
Background: Lung histopathology demonstrates vasculopathy in a subset of deceased COVID19 patients, which resembles histopathology observed in antibody-mediated lung transplant rejection. Autoantibodies against angiotensin II type 1 receptor (AT1R) and Endothelin receptor Type A (ETAR) have been demonstrated in antibody-mediated rejection and may also be associated with severe COVID19 infection. Objective To assess AT1R and ETAR auto-antibodies in COVID19 patients and controls, and explore their association with disease course. Methods: 65 hospitalized patients with COVID19 infection were included. Clinical and laboratory findings were retrospectively assessed. Patients with unfavorable disease course, admitted at the intensive care unit and/or deceased during hospital admission (n=33) were compared to admitted COVID19 patients with favorable disease course (n=32). The presence of antinuclear antibodies (ANA) and auto-antibodies against AT1R or ETAR in peripheral blood were compared between COVID19 with unfavorable and favorable disease course and age matched controls (n=20). Results: The presence of ANA was not significantly different between COVID19 patients with unfavorable (n=7/33; 21%) and favorable disease course (n=6/32; 19%) (p= 0.804) and controls (n=3/20; 15%). Auto-antibodies against AT1R were significantly increased in unfavorable disease course (median 14.59 U/mL, IQR 11.28 – 19.89) compared to favorable disease course (median 10.67 U/mL, IQR 8.55 – 13.0, p< 0.01). ETAR antibody titers were also significantly increased in unfavorable disease course (median 7.21, IQR 5.0 – 10.45) as compared to favorable disease course (median 4.0, IQR 3.0 – 6.0, p Conclusion: Auto-antibodies against AT1R and ETAR are significantly increased in COVID19 patients with an unfavorable disease course.
- 13 May 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 684142
Open AccessAntibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course
Background: Lung histopathology demonstrates vasculopathy in a subset of deceased COVID19 patients, which resembles histopathology observed in antibody-mediated lung transplant rejection. Autoantibodies against angiotensin II type 1 receptor (AT1R) and Endothelin receptor Type A (ETAR) have been demonstrated in antibody-mediated rejection and may also be associated with severe COVID19 infection. Objective To assess AT1R and ETAR auto-antibodies in COVID19 patients and controls, and explore their association with disease course. Methods: 65 hospitalized patients with COVID19 infection were included. Clinical and laboratory findings were retrospectively assessed. Patients with unfavorable disease course, admitted at the intensive care unit and/or deceased during hospital admission (n=33) were compared to admitted COVID19 patients with favorable disease course (n=32). The presence of antinuclear antibodies (ANA) and auto-antibodies against AT1R or ETAR in peripheral blood were compared between COVID19 with unfavorable and favorable disease course and age matched controls (n=20). Results: The presence of ANA was not significantly different between COVID19 patients with unfavorable (n=7/33; 21%) and favorable disease course (n=6/32; 19%) (p= 0.804) and controls (n=3/20; 15%). Auto-antibodies against AT1R were significantly increased in unfavorable disease course (median 14.59 U/mL, IQR 11.28 – 19.89) compared to favorable disease course (median 10.67 U/mL, IQR 8.55 – 13.0, p< 0.01). ETAR antibody titers were also significantly increased in unfavorable disease course (median 7.21, IQR 5.0 – 10.45) as compared to favorable disease course (median 4.0, IQR 3.0 – 6.0, p Conclusion: Auto-antibodies against AT1R and ETAR are significantly increased in COVID19 patients with an unfavorable disease course.